Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer
| dc.contributor.author | Kartal Yandım, Melis | |
| dc.contributor.author | Adan Gökbulut, Aysun | |
| dc.contributor.author | Baran, Yusuf | |
| dc.coverage.doi | 10.3109/07388551.2015.1015957 | |
| dc.date.accessioned | 2017-07-19T07:20:12Z | |
| dc.date.available | 2017-07-19T07:20:12Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | Chemotherapy is the main strategy for the treatment of cancer. However, the main problem limiting the success of chemotherapy is the development of multidrug resistance. The resistance can be intrinsic or acquired. The resistance phenotype is associated with the tumor cells that gain a cross-resistance to a large range of drugs that are structurally and functionally different. Multidrug resistance arises via many unrelated mechanisms, such as overexpression of energy-dependent efflux proteins, decrease in uptake of the agents, increase or alteration in drug targets, modification of cell cycle checkpoints, inactivation of the agents, compartmentalization of the agents, inhibition of apoptosis and aberrant bioactive sphingolipid metabolism. Exact elucidation of resistance mechanisms and molecular and biochemical approaches to overcome multidrug resistance have been a major goal in cancer research. This review comprises the mechanisms guiding multidrug resistance in cancer chemotherapy and also touches on approaches for reversing the resistance. | en_US |
| dc.identifier.citation | Kartal Yandım, M., Adan Gökbulut, A., and Baran, Y. (2016). Molecular mechanisms of drug resistance and its reversal in cancer. Critical Reviews in Biotechnology, 36(4), 716-726. doi:10.3109/07388551.2015.1015957 | en_US |
| dc.identifier.doi | 10.3109/07388551.2015.1015957 | en_US |
| dc.identifier.doi | 10.3109/07388551.2015.1015957 | |
| dc.identifier.issn | 0738-8551 | |
| dc.identifier.issn | 1549-7801 | |
| dc.identifier.scopus | 2-s2.0-84942314013 | |
| dc.identifier.uri | https://doi.org/10.3109/07388551.2015.1015957 | |
| dc.identifier.uri | https://hdl.handle.net/11147/5955 | |
| dc.language.iso | en | en_US |
| dc.publisher | Taylor and Francis Ltd. | en_US |
| dc.relation.ispartof | Critical Reviews in Biotechnology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | ABC transporters | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Bioactive sphingolipids | en_US |
| dc.subject | Cancer | en_US |
| dc.subject | Multidrug resistance | en_US |
| dc.subject | Cell cycle alteration | en_US |
| dc.title | Molecular Mechanisms of Drug Resistance and Its Reversal in Cancer | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | 0000-0002-1056-4673 | |
| gdc.author.id | 0000-0002-1056-4673 | en_US |
| gdc.author.institutional | Kartal Yandım, Melis | |
| gdc.author.institutional | Adan Gökbulut, Aysun | |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.bip.impulseclass | C3 | |
| gdc.bip.influenceclass | C4 | |
| gdc.bip.popularityclass | C2 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 726 | en_US |
| gdc.description.issue | 4 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | 716 | en_US |
| gdc.description.volume | 36 | en_US |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W1990665786 | |
| gdc.identifier.pmid | 25757878 | |
| gdc.identifier.wos | WOS:000381053900012 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.downloads | 131 | |
| gdc.oaire.impulse | 42.0 | |
| gdc.oaire.influence | 1.0830426E-8 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Cell cycle alteration | |
| gdc.oaire.keywords | cell cycle alteration | |
| gdc.oaire.keywords | Cell Cycle | |
| gdc.oaire.keywords | apoptosis | |
| gdc.oaire.keywords | Antineoplastic Agents | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | Multidrug resistance | |
| gdc.oaire.keywords | bioactive sphingolipids | |
| gdc.oaire.keywords | Drug Resistance, Multiple | |
| gdc.oaire.keywords | Membrane Lipids | |
| gdc.oaire.keywords | ABC transporters | |
| gdc.oaire.keywords | multidrug resistance | |
| gdc.oaire.keywords | Neoplasms | |
| gdc.oaire.keywords | Bioactive sphingolipids | |
| gdc.oaire.keywords | cancer | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Cancer | |
| gdc.oaire.popularity | 1.5916363E-7 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.views | 154 | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 8.07917605 | |
| gdc.openalex.normalizedpercentile | 0.98 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 277 | |
| gdc.plumx.crossrefcites | 173 | |
| gdc.plumx.mendeley | 237 | |
| gdc.plumx.pubmedcites | 136 | |
| gdc.plumx.scopuscites | 295 | |
| gdc.scopus.citedcount | 295 | |
| gdc.wos.citedcount | 278 | |
| relation.isAuthorOfPublication.latestForDiscovery | 305b031e-3047-41bb-8d20-94c588bb3a49 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |
